Skip to content
The Nexus
DossierENTITY

Kai-Keen Shiu

Coverage of Kai-Keen Shiu in the Nexus archive.

Earliest in view: May 4 · 21:02 UTCMost recent: May 4 · 21:02 UTC
Co-mentioned in this coverage
University College Londonorganization1UCL Hospitalsorganization1Yanrong Jiangperson1UCL Cancer Instituteorganization1pembrolizumabtopic1
Recent coverage
  • HEALTHMay 4 · 21:02 UTCFOX NEWS
    Patients remain cancer-free nearly 3 years after receiving experimental immunotherapy

    Patients with stage 2 or 3 bowel cancer remained cancer-free nearly three years after receiving an experimental immunotherapy treatment. The trial involved 32 patients and used a drug called pembrolizumab before surgery. The results showed that none of the patients have seen a return of the disease after almost three years of follow-up.